Engineered Microparticles for Treatment of Murine Brain Metastasis by Reprograming Tumor Microenvironment and Inhibiting MAPK Pathway
Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review
Author(s)
Related Research Unit(s)
Detail(s)
Original language | English |
---|---|
Article number | 2206212 |
Journal / Publication | Advanced Science |
Volume | 10 |
Issue number | 8 |
Online published | 25 Jan 2023 |
Publication status | Published - 15 Mar 2023 |
Link(s)
DOI | DOI |
---|---|
Attachment(s) | Documents
Publisher's Copyright Statement
|
Link to Scopus | https://www.scopus.com/record/display.uri?eid=2-s2.0-85147278153&origin=recordpage |
Permanent Link | https://scholars.cityu.edu.hk/en/publications/publication(68680d83-e55e-45e6-840e-afc528505151).html |
Abstract
Brain metastases (BRM) are common in advanced lung cancer. However, their treatment is challenging due to the blood-brain barrier (BBB) and the immunosuppressive tumor microenvironment (ITME). Microparticles (MPs), a type of extracellular vesicle, can serve as biocompatible drug delivery vehicles that can be further modulated with genetic engineering techniques. MPs prepared from cells induced with different insults are compared and it is found that radiation-treated cell-released microparticles (RMPs) achieve optimal targeting and macrophage activation. The enzyme ubiquitin-specific protease 7 (USP7), which simultaneously regulates tumor growth and reprograms M2 macrophages (M2𝚽), is found to be expressed in BRM. Engineered RMPs are then constructed that comprise: 1) the RMP carrier that targets and reprograms M2𝚽; 2) a genetically expressed SR-B1-targeting peptide for improved BBB permeability; and 3) a USP7 inhibitor to kill tumor cells and reprogram M2𝚽. These RMPs successfully cross the BBB and target M2𝚽 in vitro and in vivo in mice, effectively reprogramming M2𝚽 and improving survival in a murine BRM model. Therapeutic effects are further augmented when combined with immune checkpoint blockade. This study provides proof-of-concept for the use of genetically engineered MPs for the treatment of BRM. © 2023 The Authors. Advanced Science published by Wiley-VCH GmbH.
Research Area(s)
- blood-brain barrier, cancer immunotherapy, extracellular vesicles, macrophages polarization, USP7, MACROPHAGES, CELLS, IMMUNOTHERAPY, RADIATION, EXOSOMES, ANTIGENS
Citation Format(s)
Engineered Microparticles for Treatment of Murine Brain Metastasis by Reprograming Tumor Microenvironment and Inhibiting MAPK Pathway. / Lu, Lisen; Zi, Huaduan; Zhou, Jie et al.
In: Advanced Science, Vol. 10, No. 8, 2206212, 15.03.2023.
In: Advanced Science, Vol. 10, No. 8, 2206212, 15.03.2023.
Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review
Download Statistics
No data available